A government vaccine advisory group has recommended that teenagers be offered the meningitis B (MenB) vaccine on the NHS. This is a reversal of its position from just four months earlier and follows a series of outbreaks that killed teenagers in early 2026. The Guardian

Meningitis B is a bacterial infection that causes inflammation of the lining of the brain and spinal cord. It can spread through close contact, and it can be fatal within hours. The group that made this recommendation, the Joint Committee on Vaccination and Immunisation (JCVI), advises the UK government on which vaccines to offer and to whom.

On 16 July 2026, the JCVI, chaired by Prof Wei Shen Lim, set out a plan with several parts. For children who received a MenB jab as a baby — those born on or after 1 May 2015 — the recommendation is a booster dose around age 15. The first group under that plan will turn 15 in 2030. Children who missed the infant jab would get two doses, given at least 28 days apart. The committee also called for a catch-up programme so nobody loses out if they miss a vaccine.

The recommendation still needs government approval, and each UK nation would decide on funding and delivery on its own.

This is a major change. As of 18 March 2026, the JCVI had not recommended a routine MenB booster for teenagers, according to the UK Health Security Agency. UKHSA What happened between March and July clearly changed their thinking. The most serious outbreak hit Kent earlier in 2026 and killed two teenagers. One of them was Juliette Kenny, 18, whose family then campaigned for teenagers to routinely get the MenB vaccine.

The Kent outbreak had effects far beyond health guidance. In March 2026, pharmacies across the UK reported shortages of the MenB vaccine as demand surged, and the UK government released 20,000 NHS vaccine doses to the private market to fill the gap. Reuters

The JCVI's new recommendation for teenagers is separate from a one-off programme announced earlier in 2026. That programme offers the MenB vaccine to Year 13 pupils and to under-25 students starting university or residential education, with first doses available from 20 July 2026. UKHSA The routine recommendation, by contrast, is meant to be an ongoing vaccination schedule, not a short-term response.

Data behind the JCVI's decision suggests the MenB vaccine gives strong protection for at least five years. That matters because immunity can fade during the teenage years, which is also a period of higher risk for meningococcal disease. A booster at 15 would address that fade before young people enter university, where living in shared housing raises the chance of transmission.

The broader context here is one of policy shifting under public pressure. In March 2026, the JCVI chose not to recommend the booster while an outbreak was active and grieving families were calling for wider access. By July, the committee had recommended routine teenage vaccination, a catch-up programme, and a booster schedule. Whether the four UK health departments move quickly enough to fund and deliver the programme before the next academic year's university intake remains an open question, and one that the one-off summer programme was designed to bridge in the meantime.

Keeping the one-off programme and the routine recommendation separate also creates a risk of confusion. Families and healthcare providers will need clear communication about who is eligible, because the time-limited offer starts on 20 July while the routine booster schedule will not fully begin until 2030. The catch-up programme's scope and timeline will be especially important for teenagers currently caught in the middle — too old for the infant programme, too young for the university-targeted one-off, and facing a multi-year wait before the routine teenage schedule reaches them.